Hereditary Ovarian Cancer and Other Gynecologic Malignancies



Although the majority of gynecologic malignancies are sporadic, there is a subset of patients who develop genetic forms of gynecologic cancer. Advances in molecular biology have allowed for an understanding of the physiological pathways of development of inherited gynecologic malignancies and the identification of genetic alterations that lead to the malignant phenotype. The aim of this chapter is to help the clinician identify those patients who are at risk for developing inherited forms of gynecologic malignancies and who would benefit from screening, chemoprevention, and surgery.


Ovarian Cancer Endometrial Cancer Positive Predictive Value National Comprehensive Cancer Network Lynch Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Easton D, Ford D, Bishop D. Breast Cancer Linkage Consortium: Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995;56:265–271.PubMedGoogle Scholar
  2. 2.
    Beller U, Halle D, Catane R, et al. High frequency of BRCA1 and BRCA2 gene mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 1997;67:123–126.PubMedCrossRefGoogle Scholar
  3. 3.
    Antoniou A, Pharoah PDP, Narod S, et al. Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–1130.PubMedCrossRefGoogle Scholar
  4. 4.
    Ford D, Easton D, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676–689.PubMedCrossRefGoogle Scholar
  5. 5.
    Gayther S, Russell R, Harrington P, et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: No evidence for other ovarian cancer susceptibility genes. Am J Hum Genet 1999;65:1021–1029.PubMedCrossRefGoogle Scholar
  6. 6.
    Lallas T, Beukers T, Buller R. BRCA1 mutations in familial ovarian cancer. Mol Genet Met 1999;67:357–363.CrossRefGoogle Scholar
  7. 7.
    Reddy M, Gallion H, Fowler J, et al. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: A Gynecology Oncology Group study. Gynecol Oncol 2002;85:255–259.CrossRefGoogle Scholar
  8. 8.
    Sutcliffe S, Pharoah P, Easton D, et al. Ovarian and breast cancer risk to women in families with two or more cases of ovarian cancer. Int J Cancer 2000;87:110–117.PubMedCrossRefGoogle Scholar
  9. 9.
    Welcsh P, Owens K, King M. Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000;16:69–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Tutt A and Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002;8:571–576.PubMedCrossRefGoogle Scholar
  11. 11.
    Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 1999;386:804–810.CrossRefGoogle Scholar
  12. 12.
    Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265–275.PubMedCrossRefGoogle Scholar
  13. 13.
    Sowter HM and Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 2005;26:1651–1656.PubMedCrossRefGoogle Scholar
  14. 14.
    Stratton J, Gayther S, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997;336:1125–1130.PubMedCrossRefGoogle Scholar
  15. 15.
    Lynch H and de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919–932.PubMedCrossRefGoogle Scholar
  16. 16.
    South S, Vance H, Farrell C, et al. Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers. Cancer 2009;115:324–333.PubMedCrossRefGoogle Scholar
  17. 17.
    Malander S, Rambech E, Kristoffersson U, et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006;101:238–243.PubMedCrossRefGoogle Scholar
  18. 18.
    Shaw P, McLaughlin J, Zweemer R, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002;21:407–411.PubMedCrossRefGoogle Scholar
  19. 19.
    Young R, Dickersin G, Scully R. Juvenile granulosa cell tumor of the ovary: A clinicopathological analysis of 125 cases. Am J Surg Pathol 1984;8:575–596.PubMedCrossRefGoogle Scholar
  20. 20.
    Hartmann L, Young R, Evans M, Podratz K. Ovarian sex cord-stromal. In: Hoskins W, Perez C, Young R, eds. Principles and Practice of Gynecologic Oncology. 2nd ed. Philadelphia: Lippincott-Raven; 1997:1013–1015.Google Scholar
  21. 21.
    Raggio M, Kaplan A, Harberg J. Recurrent ovarian fibromas with basal cell nevus syndrome (Gorlin syndrome). Obstet Gynecol 1983;61:95–97.Google Scholar
  22. 22.
    Narita T, Takagi K. Ataxia telangiectasia with dysgerminoma of the right ovary, papillary carcinoma of the thyroid and adenocarcinoma of the pancreas. Cancer 1984;54:113–116.CrossRefGoogle Scholar
  23. 23.
    Troche V, Hernandez E. Neoplasia arising in dysgentic gonads. Obstet Gynecol Surv 1986;41:74–79.PubMedCrossRefGoogle Scholar
  24. 24.
    The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical Practice Guidelines in Oncology (Version 1.2009). © 2009 National Comprehensive Cancer Network, Inc. Available at: Accessed January 30, 2010.
  25. 25.
    Palma M, Ristori E, Ricevuto E, et al. BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers. Crit Rev Oncol Hemat 2006;57:1–23.CrossRefGoogle Scholar
  26. 26.
    NIH Consensus Development Panel on Ovarian Cancer. Ovarian Cancer: Screening, treatment, and follow-up. JAMA 1995;273:491–497.CrossRefGoogle Scholar
  27. 27.
    Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. Br Med J 1993;306:1030–1034.CrossRefGoogle Scholar
  28. 28.
    Olivier RI, Lubsen-Brandsma MAC, Verhoef S, and van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20–26.PubMedCrossRefGoogle Scholar
  29. 29.
    Einhorn N, Sjovall K, Knapp RC, et al. Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14–18.PubMedGoogle Scholar
  30. 30.
    Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995;76:2004–2010.PubMedCrossRefGoogle Scholar
  31. 31.
    Menon U, Skates S, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919–7926.PubMedCrossRefGoogle Scholar
  32. 32.
    Van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk of ovarian cancer [see comments]. Gynecol Oncol 2000;77:350–356.PubMedCrossRefGoogle Scholar
  33. 33.
    Sato S, Yokoyama Y, Sakamoto T, et al. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000;89:582–588.PubMedCrossRefGoogle Scholar
  34. 34.
    Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695–3700.PubMedGoogle Scholar
  35. 35.
    Moore A, Brown M, Miller S, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2007;108:402–408.PubMedCrossRefGoogle Scholar
  36. 36.
    McIntosh M, Drescher C, Karlan B, et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9–15.PubMedCrossRefGoogle Scholar
  37. 37.
    Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065–1072.PubMedCrossRefGoogle Scholar
  38. 38.
    Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol 2006;49:433–447.PubMedCrossRefGoogle Scholar
  39. 39.
    Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: Cancer prevention through apoptosis? J Soc Gynecol Invest 1998;5:271–276.CrossRefGoogle Scholar
  40. 40.
    Ness RB, Grisso JA, Vergona R, et al. Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 2001;12:307–312.PubMedCrossRefGoogle Scholar
  41. 41.
    Siskind V, Green A, Bain C, et al. Beyond ovulation: Oral contraceptives and epithelial ovarian cancer. Epidemiology 2000;11:106–110.PubMedCrossRefGoogle Scholar
  42. 42.
    Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424–428.PubMedCrossRefGoogle Scholar
  43. 43.
    Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study. Br J Cancer 1995;71:1340–1342.PubMedCrossRefGoogle Scholar
  44. 44.
    Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995;76:284–290.PubMedCrossRefGoogle Scholar
  45. 45.
    Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994;139:654–661.PubMedGoogle Scholar
  46. 46.
    John EM, Whittemore AS, Harris R, et al. Characteristics relating to ovarian cancer risk: Collaborative analysis of seven US case control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. JNCI 1993;85:142–147.PubMedCrossRefGoogle Scholar
  47. 47.
    Parazzini F, La Vechia C, Negri E, et al. Oral contraceptive use and the risk of ovarian cancer: An Italian case control study. Eur J Cancer 1991;27:594–598.PubMedCrossRefGoogle Scholar
  48. 48.
    Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. Oral contraceptive use. Int J Cancer 1991;49:61–65.PubMedCrossRefGoogle Scholar
  49. 49.
    Parazzini F, Restelli C, La Vechia C, et al. Risk factors for epithelial ovarian tumors of borderline malignancy. Int J Epidemiol 1991;20:871–877.PubMedCrossRefGoogle Scholar
  50. 50.
    Gwinn ML, Lee NC, Rhodes PH. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990;43:559–568.PubMedCrossRefGoogle Scholar
  51. 51.
    The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction of risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987;316:650–655.CrossRefGoogle Scholar
  52. 52.
    Wu ML, Whittemore AS, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer: Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988;128:1216–1227.PubMedGoogle Scholar
  53. 53.
    Gross TP, Schlesselman JJ, Stadel BV, et al. The risk of epithelial ovarian cancer in short-term users of oral contraceptives. Am J Epidemiol 1992;136:46–53.PubMedGoogle Scholar
  54. 54.
    Hartge P, Whittemore A, Itnyre J, et al. Rates and risk of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. Obstet Gynecol 1994;84:760–764.PubMedGoogle Scholar
  55. 55.
    Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid hormones and reproductions. Am J Epidemiol 2000;152:233–241.PubMedCrossRefGoogle Scholar
  56. 56.
    Lurie G, Thompson P, McDuffie KE, et al. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol 2007;109:597–607.PubMedCrossRefGoogle Scholar
  57. 57.
    Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of ovarian cancer. Obstet Gynecol 1994;83:419–424.PubMedGoogle Scholar
  58. 58.
    Tavani A, Ricci E, La Vechia C, et al. Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol 2000;29:799–802.PubMedCrossRefGoogle Scholar
  59. 59.
    Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235–240.PubMedCrossRefGoogle Scholar
  60. 60.
    Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with BRCA1 or BRCA2 mutations. JAMA 2006;296:185–192.PubMedCrossRefGoogle Scholar
  61. 61.
    Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–1622.PubMedCrossRefGoogle Scholar
  62. 62.
    Kauff ND, Satagopan JM, Robson M, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–1615.PubMedCrossRefGoogle Scholar
  63. 63.
    SGO Committee Statement. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. Gynecol Oncol 2005;98:179–181.CrossRefGoogle Scholar
  64. 64.
    Schrag D, Kuntz KM, Garber JE, et al. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465–1471.PubMedCrossRefGoogle Scholar
  65. 65.
    Lamb JD, Garcia RL, Goff BA, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol 2006;194:1702–1709.PubMedCrossRefGoogle Scholar
  66. 66.
    Aziz S, Kuperstein G, Rose B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341–345.PubMedCrossRefGoogle Scholar
  67. 67.
    Karlan BY. Defining cancer risks for BRCA germline mutation carriers: Implications for surgical prophylaxis. Gynecol Oncol 2004;92:519–520.PubMedCrossRefGoogle Scholar
  68. 68.
    Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:2751–2755.PubMedCrossRefGoogle Scholar
  69. 69.
    Cornelison T, Natarajan N, Piver M, et al. Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev 1997;21:1–6.PubMedGoogle Scholar
  70. 70.
    Hankinson S, Hunter D, Colditz G, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993;270:2813–2818.PubMedCrossRefGoogle Scholar
  71. 71.
    Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet 2001;357:1467–1470.PubMedCrossRefGoogle Scholar
  72. 72.
    Miracle-McMahill HL, Calle EE, Kosinski AS, et al. Tubal ligation and fatal ovarian cancer in a larger prospective cohort study. Am J Epidemiol 1997;14:349–357.CrossRefGoogle Scholar
  73. 73.
    Green A, Purdie D, Bain C, et al. Tubal sterilization, hysterectomy and decreased risk of ovarian cancer: Survey of women’s health study group. Int J Cancer 1997;71:948–951.PubMedCrossRefGoogle Scholar
  74. 74.
    Rosenblatt KA and Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy: The World Health Organization collaborative study of neoplasia and steroid contraceptives. Cancer Epidemiol Biomarkers Prev 1996;5:933–935.PubMedGoogle Scholar
  75. 75.
    Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214–218.PubMedCrossRefGoogle Scholar
  76. 76.
    Watson P, Vasen HFA, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994;96:516–520.PubMedCrossRefGoogle Scholar
  77. 77.
    Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC. Cancer 2006;106:87–94.PubMedCrossRefGoogle Scholar
  78. 78.
    Boks DE, Trujillo AP, Voogd AC, et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002;102:198–200.PubMedCrossRefGoogle Scholar
  79. 79.
    Walsh C, Blum A, Walts A, et al. Lynch syndrome among gynecology patients meeting Bethesda guidelines for screening. Gynecol Oncol 2009;doi:10.1016/j.gyno. 2009.11.021.Google Scholar
  80. 80.
    Abdel-Rahman WM, Mecklin JP, Peltomaki P. The genetics of HNPCC: Application to diagnosis and screening. Crit Rev Oncol Hematol 2006;58:208–220.PubMedCrossRefGoogle Scholar
  81. 81.
    Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94:1708–1712.PubMedCrossRefGoogle Scholar
  82. 82.
    Lindor LM, Peterson GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 2009;296:1507–1517.CrossRefGoogle Scholar
  83. 83.
    Van den Bosch T, Van den Dael A, Van Schouboreck D, et al. Combining vaginal ultrasonography and office endometrial sampling in the diagnosis of endometrial disease in postmenopausal women. Obstet Gynecol 1995;85:349–352.PubMedCrossRefGoogle Scholar
  84. 84.
    Schmeler KM, Lynch HT, Chen L, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261–269.PubMedCrossRefGoogle Scholar
  85. 85.
    Gilks C, Young R, Aguirre P, et al. Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix: A clinicopathological and immunohistochemical analysis of 26 cases. Am J Surg Pathol 1989;13:707–714.CrossRefGoogle Scholar
  86. 86.
    Kaminsky P and Norris H. Minimal deviation carcinoma (adenoma malignum) of the cervix. Int J Gynecol Pathol 1983;12:141–145.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Obstetrics, Gynecology and Women’s HealthUniversity of Louisville HospitalLouisvilleUSA

Personalised recommendations